Novel developments in stem cell mobilization: focus on CXCR4

Recently the CXCR4/CXCL12-axis has been recognized as one of the pivotal adhesion pathways by which hematopoietic stem cells are retained in the bone marrow. CXCR4 antagonists with different chemical specification are being developed. Pharmacology research guides the way to the rational development effective antagonists. One antagonist, plerixafor, is clinically approved now for stem cell mobilization of lymphoma and myeloma patients. This allows patients to receive potentially life-saving treatment which could not have been administered otherwise. Through early clinical studies it was recognized that CXCR4 antagonists also mobilize malignant hematopoetic cells, i.e. leukemia cells. In preclinical studies a sensitization of mobilized leukemic cells to standard cytotoxic chemotherapy could be shown. Clinical studies are under way. CXCR4 antagonists are an exciting new class of compounds which are also employed for the mobilization of angiogenic cells or for the treatment of solid tumors. In this book a concise review of the current status of knowledge and future developments will be presented. A concise review of the current status of knowledge and future developments of CXCR4 will be presented. Contributors are internationally leaders in the field. A comprehensive treatment of the subject with numerous color illustrations. INDICE: Preface. Preclinical Experience with AMD3100 for Mobilization of Hematopoietic Stem and Progenitor Cells. Molecular Pharmacology of CXCR4 Inhibition. Combination Strategies for Stem Cell Mobilization Targeting CXCR4 and S1P Receptors. Should We Stay Or Should We Go Now?. Cell Adhesion and Mobilization Pathways of Hematopoietic Cellls. Role of the CXCR4/CXCL12 Axis in Hematopoietic Stem Cell Trafficking. Early Studies of AMD3100/Plerixafor in Healthy Volunteers. The Current Role of Plerixafor in Stem Cell Mobilization for Hematopoietic Stem Cell Transplantation. Relevance and Clinical Implications of TumorCell Mobilization in Autologous Transplantation of Multiple Myeloma and non Hodgkin's lymphoma. Plerixafor - Data from the Compassionate Use Program. StemCell Mobilization with Chemomobilization plus Plerixafor in Hard-To-Mobilize Patients - The Experience at Kuopio University Hospital, Finland. Blood Stem Cell Mobilization in Solid Tumors - Experience with Plerixafor and Alternative Ways of Hematopoietic Stem Cell Mobilization. Mobilization with Chemotherapy+G-CSF+Plerixafor in Europe- the Italian experience. Experience with Plerixafor in Poor Mobilizers. CXCR4 Antagonists. Application of CXCR4-Inhibitors in Leukemia. CXCR4 Antagonists for the Treatment of CML. Targeting CXCR4 in Chronic Lymphocytic Leukemia (CLL): Preclinical Rationale and Early Clinical Experience. CXCR4-Blockade for Treatment of Breast Cancer. Molecular Imaging of CXCR4 Receptor Expression in Tumors. Potential Use of CXCR4 Antagonists to Mobilize Endothelial and Mesenchymal Stem Cells. Strategies to Enhance Hematopoietic StemCell Engraftment Following Transplantation. Mobilization for Gene Therapy. Index.

• ISBN: 978-1-4614-1959-4
• Editorial: Springer New York
• Encuadernacion: Cartoné
• Páginas: 534
• Fecha Publicación: 28/12/2011
• Nº Volúmenes: 1
• Idioma: Inglés